All News

"There is no simple or universal answer to the question of retirement savings. Many factors must be considered, but your financial adviser should be able to direct you so that you can enjoy a financially stable life once you stop working," writes Jeff Witz, CFP.

"It is unique given that in addition to providing prognostic information, it can serve as a marker to predict sensitivity to androgen deprivation therapy (ADT), which is the backbone of systemic therapy for men with prostate cancer," says Rana R. McKay, MD.

The tool uses clinical covariates to predict changes in storage, voiding, and nocturia LUTS for patients receiving placebo, dutasteride, tamsulosin, or DUT/TAM combination therapy.

The phase 3 RENOTORCH study is comparing the combination of the PD1-inhibitor toripalimab and axitinib with single-agent sunitinib in patients with renal cell carcinoma.

"Proxies for social determinants of health that we found to be associated with higher overall mortality included living in a more deprived area, as well as having Medicaid or Medicare insurance," says David Miller, MD.

Vivally System is a neuromodulation system that uses a closed-loop control algorithm and electromyography to personalize treatment for each patient.

In the ARASTEP trial, the primary outcome measure of rPFS is being measured by PSMA-PET/CT imaging with 68Ga-PSMA-11 (prepared using Illuccix) or piflufolastat F 18.

Here are some ways in which lawyers can remove potential jurors from a case.

"The study demonstrated that AS rate in the MUSIC cohort, which in 2014 had been lower than in the SEER cohort, increased rapidly, from approximately 20% in 2014 to nearly 50% in 2019, whereas the SEER cohort showed only a modest increase," writes Badar M. Mian, MD.

The addition of STAD did, however, improve secondary end points, including metastases rates, prostate cancer-specific mortality, and PSA failure.

Illuccix is approved by Health Canada for imaging in patients with suspected metastasis who are candidates for initial definitive therapy, or in patients with suspected recurrence based on an elevated PSA level.

The methylation-based urine test is performed on a qPCR platform and is intended for use in conjunction with cystoscopy.

"The most important thing for transgender women and their health care providers to remember is that prostate cancer screening shouldn’t be neglected," said Stephen J. Freedland, MD.

Treatment with the Optilume BPH System resulted in significant, immediate symptomatic and functional improvements in patients with BPH, according to 12-month data from the PINNACLE study.

Among medical groups, 65% said they will employ advanced practice providers in 2023.

“The ARAMIS Rollover Study extended the duration of darolutamide treatment and demonstrated the long-term safety of darolutamide in patients with [nonmetastatic CRPC],” said Neal D. Shore, MD.

Preliminary findings from the single-arm, phase 2 CORE-001 trial showed that the combination of the oncolytic immunotherapy cretostimogene grenadenorepvec (CG0070) and pembrolizumab (Keytruda) elicited a high complete response rate in patients with BCG–unresponsive non–muscle invasive bladder cancer.

“The combination of sintilimab and axitinib had a manageable safety profile and achieved a promising tumor response rate in patient with advanced FH-deficient RCC,” said Xingming Zhang.

Data from the retrospective DEAR study linked darolutamide to lower rates of discontinuation and progression to metastatic disease vs enzalutamide and apalutamide in patients with nonmetastatic castration-resistant prostate cancer.

“The results of the study imply that UGN-101 is not only a renal-preserving therapy for UTUC in this comorbid population, but could potentially delay the time to dialysis or radical nephroureterectomy," says Kyle M. Rose, MD.

The indication is restricted from the indication in the FDA supplemental New Drug Application for olaparib/abiraterone, which is for the population at-large in the BRCA–mutation positive setting.

"At our institution, we used a [quality improvement] protocol to first decrease overall antibiotic duration from the more standard 30 days, and then we further decreased it along with ureteral stent decrease,” says Jessica Wenzel, MD, MPH.

“This is a pivotal phase 3 trial that I think is going to be practice changing to the urology community,” said Brian Shuch, MD.

Adding apalutamide to ADT with or without abiraterone acetate/prednisone significantly prolonged PSA PFS in men with biochemically relapsed prostate cancer, according to extended follow-up from the phase 3 PRESTO study.

"PRP does not seem to be effective in treating men with erectile dysfunction, at least as a monotherapy,” said Ranjith Ramasamy, MD.

“Zenflow is a novel minimally invasive surgical therapy that delivers a nitinol device into the prostatic urethra displacing the lateral lobes for improved urinary flow,” explained Dean Elterman, MD.

Beyond demonstrating clinical activity, pembrolizumab was safe and tolerable in this patient population.

“These results further support nivolumab as a standard of care for high-risk MIUC and MIBC after radical resection,” said Matthew Milowsky, MD.